Prof. HALE GÖKCAN

Publication Network

Articles 77

1. Pre-transplant predictors of 3-Month survival following liver transplantation for acute liver failure in adult and pediatric patients in Türkiye

Turan İ., Akarca U. S., Aladağ M., Harputluoğlu M., YILMAZ S., Gençdal G., et al.

Scientific Reports , vol.15, no.1, 2025 (SCI-Expanded, Scopus)

2. The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virusrelated cirrhosis

Kilic G., Guvenir T., BODAKÇİ E., MELEKOĞLU ELLİK Z., GÖKCAN H., İDİLMAN R.

Hepatology Forum , vol.6, no.4, pp.141-145, 2025 (Scopus)

3. Histological disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy.

Turan Gokce D., Ekelik M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.

European journal of gastroenterology & hepatology , 2025 (SCI-Expanded, Scopus)

4. Mushroom Intoxication in Türkiye: A Nationwide Cohort Study Based on Demographic Trends, Seasonal Variations, and the Impact of Climate Change on Incidence

Gökçe D., Ari D., Ata N., GÖKCAN H., İDİLMAN R., Ülgü M. M., et al.

Turkish Journal of Gastroenterology , vol.36, no.1, pp.61-66, 2025 (SCI-Expanded, Scopus, TRDizin)

5. Assessing hepatic steatosis by magnetic resonance in potential living liver donors

Kuru Öz D., Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Kiremitci S., et al.

Diagnostic and Interventional Radiology , vol.30, no.6, pp.351-356, 2024 (SCI-Expanded, Scopus, TRDizin)

6. HEPATIC STEATOSIS IS ASSOCIATED WITH HBSAG CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

BODAKÇİ E., KİREMİTCİ S., DUMAN S., MELEKOĞLU ELLİK Z., Gumussoy M., GÜVENİR S. T., et al.

HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

7. ASSESSMENT OF THE RELATIONSHIP BETWEEN MRI-BASED INTRAMUSCULAR FAT INDICATING SARCOPENIA IN VARIOUS MUSCLE GROUPS AMONG PATIENTS WITH CHRONIC LIVER DISEASE

Er R. E., Akkaya Z., Ünal S., Kuru Öz D., Çelebi M. M., Gökcan H., et al.

HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

8. A Brief Communication of Patients of Patients with Homozygous C282Y Mutation-Related Hereditary Hemochromatosis.

GÖKCAN H., Öz d. K., BODAKÇİ E., İDİLMAN R.

Hepatology forum , vol.5, pp.161-164, 2024 (ESCI, Scopus, TRDizin)

9. A brief communication of patients with homozygous C282Y mutation-related hereditary hemochromatosis

GÖKCAN H., Oz D., BODAKÇİ E., TUNÇ E., İDİLMAN R.

HEPATOLOGY FORUM , vol.5, no.3, pp.161-164, 2024 (ESCI, Scopus, TRDizin)

10. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone

Duman S., Kuru D., Gumussoy M., KİREMİTCİ S., GÖKCAN H., Ulas B., et al.

EUROPEAN RADIOLOGY , vol.34, no.6, pp.3882-3888, 2024 (SCI-Expanded, Scopus)

11. Recurrence of primary sclerosing cholangitis after living donor liver transplantation: experience from turkish registry

Adali G., Harputluoglu M., Kayhan M. A., Gokce D. T., AKARSU M., Daniscomma N., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

12. Histological and clinical disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy

Ekelik M., Gökçe D. T., Gumussoy M., Kiremitçi S., Bodakçi E., Yılmaz V., et al.

JOURNAL OF HEPATOLOGY , vol.80, pp.479, 2024 (SCI-Expanded, Scopus)

13. Histological and clinical disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy

Ekelik M., Gokce D. T., Gumussoy M., KİREMİTCİ S., Bodakci E., Yilmaz V., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

14. DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE USING PAIRED LIVER BIOPSY

Turan D., Ekelik M. M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.

GASTROENTEROLOGY , vol.166, no.5, pp.1642, 2024 (SCI-Expanded, Scopus)

15. Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study

Akarsu M., DOLU S., Harputluoglu M., YILMAZ S., Akyildiz M., Gencdal G., et al.

HEPATOLOGY FORUM , vol.5, no.1, pp.3-6, 2024 (ESCI, Scopus)

16. Multidrug-Resistant Infections After Liver Transplantation, Etiology and Risk Factors: A Single-Center Experience

Tezcan H., Altunsoy A., Gokce D., GÖKCAN H., Ari D., Aydin O., et al.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION , vol.21, no.12, pp.952-960, 2023 (SCI-Expanded, Scopus)

17. Pancreatic metastasis of renal cell carcinoma: case report

Gökcan H.

Journal of Current Hematology & Oncology Research , vol.1, no.4, pp.109-110, 2023 (Peer-Reviewed Journal)

18. Hepatoselüler kanser, Güncel yenilikler

GÖKCAN H.

Güncel Gastroenteroloji , vol.25, no.2, pp.75-89, 2023 (Peer-Reviewed Journal)

19. Post traumatic volvulus: a case report

Gökcan H.

Journal of Comprehensive Surgery , vol.1, pp.60-62, 2023 (Peer-Reviewed Journal)

20. Development of metabolic disorders in transplant recipients

Erdemir G., GÖKCAN H., GÜRSOY ÇORUH A., GÜLPINAR B., Ellik Z., Gumussoy M., et al.

JOURNAL OF HEPATOLOGY , vol.78, 2023 (SCI-Expanded, Scopus)

21. Identification of risk factors for alcohol relapse in liver transplant patients with alcohol-related liver disease

Turan D., GÜNŞAR F., Harputluoglu M., Kabacam G., Gokcan H., Akyildiz M., et al.

JOURNAL OF HEPATOLOGY , vol.78, 2023 (SCI-Expanded, Scopus)

22. TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.

YILMAZ Y., ZEYBEL M., ADALI G., COŞAR A., SERTESEN E., SÜMER H., et al.

Hepatology forum , vol.4, no.Suppl 1, pp.1-32, 2023 (ESCI, TRDizin)

23. Management of Biliary Complications in Liver Transplant Recipients with Duct-To-Duct Anastomosis: A Single-Center Experience

Karakaya M. F., Er E., Kırımker O., Gümüşsoy M., Bodakçi E., Özercan M., et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , vol.34, no.2, pp.177-181, 2023 (SCI-Expanded, Scopus, TRDizin)

24. Effect of Pretransplant Sarcopenia on Mortality in Liver Transplant Recipients

Arı D., Dağlı M., GÖKCAN H., Gökçe D., Ökten R. S., Aydın O., et al.

Experimental and Clinical Transplantation , vol.21, no.2, pp.123-131, 2023 (SCI-Expanded, Scopus)

25. The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

Yaras S., Demir M., Barutcu S., Yildirim A. E., GÜREL S., Ucbilek E., et al.

Hepatology Forum , vol.4, no.3, pp.92-96, 2023 (Scopus)

26. Complete Recovery After Immunosuppressive Treatment Change in a Patient With Posttransplant Lymphoproliferative Disorder

Arı D., Turan D., GÖKCAN H., Özdemir M., Kayhan M. A.

Experimental and Clinical Transplantation , vol.21, no.1, pp.76-79, 2023 (SCI-Expanded, Scopus)

27. Rare hepatocellular carcinoma presentation: Hepatoportal sclerosis

Gokce D., Ari D., GÖKCAN H., Aydin O., Turhan N., Kayhan M. A.

HEPATOLOGY FORUM , vol.4, no.1, pp.35-36, 2023 (ESCI, Scopus, TRDizin)

28. Lymphocyte count and NLR as predictive value for the severity of acute cholangitis

Yeşil B., Çalişkan A., Koşar K., Yüksel M., GÖKCAN H., Tümtürk A., et al.

European Review for Medical and Pharmacological Sciences , vol.27, no.18, pp.8732-8739, 2023 (SCI-Expanded, Scopus)

29. The changing non-invasive fibrosis index value in patients with hepatitis C treated with direct-acting antiviral agents

Ari D., Gökçe D. T., Gökcan H., Öztürk Ö., Bacaksiz F., Kacar S., et al.

Akademik Gastroenteroloji Dergisi , vol.21, no.3, pp.109-114, 2022 (TRDizin)

30. Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study

Gumussoy M., Koc O., KARATAŞ G., Ozercan M., Ellik Z., DUMAN S., et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , vol.34, no.11, pp.1172-1177, 2022 (SCI-Expanded, Scopus)

31. NATURAL DISEASE OUTCOMES IN PATIENT WITH NONALCOHOLIC FATTY LIVER DISEASE: A STUDY WITH PAIRED LIVER BIOPSIES

Gumussoy M., Gokce D., Ekelik M., KİREMİTCİ S., Bodakci E., DUMAN S., et al.

HEPATOLOGY , vol.76, 2022 (SCI-Expanded, Scopus)

32. EFFECT OF PROGNOSTIC NONINVASIVE TESTS ON DISEASE OUTCOME OF ALCOHOL-RELATED LIVER DISEASE

Zengin B. A., Gumussoy M., Duman S., Bodakçi E., Güvenir S. T., Ellik Z., et al.

HEPATOLOGY , 2022 (SCI-Expanded, Scopus)

33. Characteristics of patients with hepatocellular carcinoma: A multicenter study

Guzelbulut F., KARAOĞULLARINDAN Ü., AKKIZ H., ALTINTAŞ E., DEMİRTAŞ C. Ö., Bahadir O., et al.

HEPATOLOGY FORUM , vol.3, no.3, pp.71-76, 2022 (ESCI, Scopus, TRDizin)

34. NSAID-associated drug-induced liver injury prior to and following liver transplantation

Gumussoy M., GÖKCAN H., BODAKÇİ E., KİREMİTCİ S., SAVAŞ B., İDİLMAN R.

HEPATOLOGY FORUM , vol.3, no.3, pp.108-109, 2022 (ESCI)

35. Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors

KURU ÖZ D., Ellik Z. M., Coruh A. G., ADIGÜZEL M., Gumussoy M., DUMAN S., et al.

JOURNAL OF HEPATOLOGY , vol.77, 2022 (SCI-Expanded, Scopus)

36. Our Experience with Patients That Diagnosed Ischemic Colitis in Colonoscopy

Gökbulut V., Kaplan M., Disibeyaz S., Kacar S., Gökcan H., Gökbulut P., et al.

Journal of Contemporary Medicine , vol.12, no.1, pp.38-43, 2022 (Peer-Reviewed Journal)

37. Evaluation of esophageal motor functions in patients diagnosed with primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis

Gokbulut V., Ozturk O., Akdogan M., Kaplan M., GÖKCAN H., Kacar S., et al.

CUKUROVA MEDICAL JOURNAL , vol.47, no.1, pp.21-28, 2022 (ESCI, TRDizin)

38. Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients

Bacaksiz F., GÖKCAN H., Akdogan M., Gokce D., Ari D., Gokbulut V., et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.75, no.12, 2021 (SCI-Expanded, Scopus)

39. HBV/HDV management after liver transplantation: Review

Muhammad H., Zaffar D., Tehreem A., Peng-Sheng T., ŞİMŞEK C., GÖKCAN H., et al.

Journal of Liver Transplantation , 2021 (Peer-Reviewed Journal)

40. Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

AKARSU M., Onem S., TURAN İ., Adali G., Akdogan M., Akyildiz M., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.32, no.9, pp.712-719, 2021 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

41. Hepatitis D Infection in Asia: A Perspective From an Endemic Region

GÖKCAN H., İDİLMAN R.

Clinical Liver Disease , vol.18, no.1, pp.26-29, 2021 (Scopus) Sustainable Development

42. Association between non-alcoholic fatty liver disease and extrahepatic malignancy

Gumussoy M., İDİLMAN R., GÖKCAN H., Gokce D., Ulas B. B., Koc O., et al.

JOURNAL OF HEPATOLOGY , vol.75, 2021 (SCI-Expanded, Scopus)

43. The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study

YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA M. F., GÖKCAN H., KAYA E., et al.

Hepatology forum , vol.2, no.2, pp.37-42, 2021 (ESCI, Scopus)

44. Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

Degertekin B., DEMİR M., AKARCA U. S., Kani H. T., ÜÇBİLEK E., Yildirim E., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.12, pp.883-893, 2020 (SCI-Expanded, Scopus, TRDizin)

45. Gastrointestinal Subepitelyal Lezyonlarda Tedavi ve İzlem Algoritmi Treatment and Monitoring of Gastrointestinal Subepitelial Lesions

ARI D., GÖKCAN H., AKDOĞAN KAYHAN M.

Türkiye Klinikleri Gastroenterohepatoloji Dergisi , pp.72-76, 2020 (Non Peer-Reviewed Journal)

46. Effectiveness of Technetium-99 m monoclonal antibody scintigraphy for the detection of infectious focus in a case series in cirrhotic patients

GÖKCAN H., AKTAŞ A., ÖZTÜRK Ö., SAVAŞ N.

Hepatology forum , vol.2, no.1, pp.75-78, 2020 (ESCI, Scopus)

47. Prevalence and characteristics of bone disease in cirrhotic patients

GÖKCAN H., Kayhan M. A., Demir S. O., Kacar S., Cam P., Kaplan M., et al.

HEPATOLOGY FORUM , vol.1, no.2, pp.48-52, 2020 (ESCI, Scopus)

48. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

İDİLMAN R., DEMİR M., ALADAĞ M., Erol C., Cavus B., Iliaz R., et al.

JOURNAL OF VIRAL HEPATITIS , vol.26, no.6, pp.666-674, 2019 (SCI-Expanded, Scopus) Sustainable Development

49. Mallory-Weiss Sendromunda Tanı, Klinik Seyir ve Endoskopik Tedavi

Gökcan H.

Endoskopi Gastrointestinal , vol.26, no.2, pp.41-45, 2018 (TRDizin)

50. Effects of preoperative endoscopic pneumatic balloon dilatation on postoperative achalasia symptoms after Heller esophageal myotomy plus Dor fundoplication

Gokcan H.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.29, no.5, pp.526-529, 2018 (SCI-Expanded, Scopus, TRDizin)

51. Prognostic Utility of Hypokalemia in Cirrhotic Patients

Kaplan M., Ates I., Gokcan H., Kayhan M. A., Kacari S., Akpinar M. Y., et al.

ACTA GASTRO-ENTEROLOGICA BELGICA , no.3, pp.398-403, 2018 (SCI-Expanded)

52. Primer Biliyer Kolanjit Hastalarında Tedaviye Yanıt Kriterlerinin Değerlendirilmesi

YÜKSEL M., YILDIZ H., AKDOĞAN KAYHAN M., Kacar S., KILIÇ Z. M. Y., ÖZTAŞ E., et al.

Akademik Gastroenteroloji Dergisi , vol.16, pp.24-29, 2017 (TRDizin)

53. Primer sklerozan kolanjiti taklit eden otoimmün kolanjiyopati: Vaka sunumu

Akpınar M. Y., Ödemiş B., Kacar S., GÖKCAN H., KUZU U. B.

Akademik Gastroenteroloji Dergisi , 2016 (TRDizin)

54. GASTROINTESTINAL STROMAL TUMOR IN A YOUNG MAN WITH SEVERE HEMATEMESIS : A CASE STUDY

kuzu U. B., Suna N., Torun S., Gokcan H., Oztas E., Odemis B.

GASTROENTEROLOGY NURSING , vol.39, no.5, pp.397-399, 2016 (SCI-Expanded, SSCI, Scopus)

55. Pregabalin: A New Adjunct in Calcineurin Inhibitor Pain Syndrome Treatment

Tasoglu O., Gokcan H., Demir S. O., Yenigun D., Akdogan M., Kacar S.

PROGRESS IN TRANSPLANTATION , vol.26, no.3, pp.224-226, 2016 (SCI-Expanded, Scopus)

56. Noninvasive indirect serum markers of liver fibrosis in patients with chronic viral hepatitis Reply

Gokcan H., Kuzu U. B., Oztas E., Saygili F., Oztuna D., Suna N., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , no.4, pp.398, 2016 (SCI-Expanded, Scopus, TRDizin)

57. Case of a successful liver transplantation from a living donor with focal nodular hyperplasia

Gokcan H., Akdogan M., Kacar S., Okten R. S., Ozdemir M., Turhan N., et al.

ACTA GASTRO-ENTEROLOGICA BELGICA , vol.79, no.2, pp.262-263, 2016 (SCI-Expanded, Scopus)

58. The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C

Gokcan H., Kuzu U. B., Oztas E., Saygili F., Oztuna D., Suna N., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , no.2, pp.156-164, 2016 (SCI-Expanded, Scopus, TRDizin)

59. Porcelain Gallbladder

Akpınar M. Y., KAPLAN M., GÖKCAN H., Erkan V., KAYAÇETİN E.

Akademik Gastroenteroloji Dergisi , 2016 (TRDizin)

60. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety

Gokcan H., Oztas E., Onal I. K.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY , vol.40, no.1, pp.124-131, 2016 (SCI-Expanded, Scopus)

61. Metastases of malignant melanoma to stomach

Kuzu U. B., Suna N., Gokcan H., Abdullazade S., Oztas E., Odemis B.

GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY , vol.11, no.1, pp.54-55, 2016 (ESCI, Scopus)

62. Hepatit C’li hastalarda ortalama trombosit hacmi ve nötrofil-lenfosit oranının anlamlı fibrozis tanısında etkinliği

KUZU U. B., ÖZTAŞ E., SUNA N., Sırtaş Z., YILDIZ H., Akpınar M. Y., et al.

Akademik Gastroenteroloji Dergisi , 2015 (TRDizin)

63. Predictors of Survival in Hepatocellular Carcinoma Patients

Gokcan H., Savas N., Oztuna D., Moray G., Boyvat F., HABERAL M.

ANNALS OF TRANSPLANTATION , pp.596-603, 2015 (SCI-Expanded, Scopus)

64. Predictive Value of Unenhanced Computerized Tomography for Detecting Hepatosteatosis in Living Liver Donors

Kuzu U. B., Gokcan H., Suna N., Ozdemir M., Yildiz H., Kacar S., et al.

TRANSPLANTATION PROCEEDINGS , no.6, pp.1854-1859, 2015 (SCI-Expanded, Scopus)

65. Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis

Gokcan H., Yurtcu E., Selcuk H., Sahin F. I.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES , vol.15, no.2, pp.73-77, 2015 (SCI-Expanded, Scopus)

66. The Nutritional Risk Screening 2002 tool for detecting malnutrition risk in hospitalised patients: Perspective from a developing country

Gokcan H., Selcuk H., Tore E., Gulseren P., Cambaz H., Saritas S., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.25, no.6, pp.718-723, 2014 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

67. What is the impact of Helicobacter pylori density on the success of eradication therapy: A clinico-histopathological study

Onal I. K., Gokcan H., Benzer E., Bilir G., Oztas E.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY , vol.37, no.6, pp.642-646, 2013 (SCI-Expanded, Scopus)

68. A case of eosinophilic gastritis secondary to ulcerative colitis

Gokcan H., Uruc I., Selcuk H., Savas N., Yilmaz U.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.21, no.1, pp.69-70, 2010 (SCI-Expanded, Scopus, TRDizin)

69. Detection of MEFV Gene Mutations in Patients with Inflammatory Bowel Disease

Yurtcu E., Gokcan H., Yilmaz U., ŞAHİN F. İ.

GENETIC TESTING AND MOLECULAR BIOMARKERS , vol.13, no.1, pp.87-90, 2009 (SCI-Expanded, Scopus)

70. Total colonic polyp diameter: A marker for the risk of malignancy?

Selcuk H., Korkmaz M., Kanbay M., Tore E., Sumer H., UNAL H. U., et al.

HEPATO-GASTROENTEROLOGY , vol.55, no.84, pp.936-939, 2008 (SCI-Expanded, Scopus)

71. Malignancy risk of small polyps and related factors

UNAL H. U., Selcuk H., Gokcan H., Tore E., Sar A., Korkmaz M., et al.

DIGESTIVE DISEASES AND SCIENCES , vol.52, no.10, pp.2796-2799, 2007 (SCI-Expanded, Scopus)

72. Dipeptidyl peptidase IV (DDP IV) in NASH patients

BALABAN H. Y., KORKUSUZ P., Simsek H., Gokcan H., Gedikoglu G., Pinar A., et al.

ANNALS OF HEPATOLOGY , vol.6, no.4, pp.242-250, 2007 (SCI-Expanded, Scopus)

73. HFE mutations analysis of Turkish patients with nonalcoholic steatohepatitis

Simsek H., BALABAN H. Y., Sumer H., Yilmaz E., Tatar G.

DIGESTIVE DISEASES AND SCIENCES , no.10, pp.1723-1724, 2006 (SCI-Expanded, Scopus)

74. Mutations of the HFE gene among Turkish hereditary hemochromatosis patients

Simsek H., BALABAN H. Y., Yilmaz E., Sumer H., Buyukasik Y., Cengiz C., et al.

ANNALS OF HEMATOLOGY , vol.84, no.10, pp.646-649, 2005 (SCI-Expanded, Scopus)

75. Bone marrow embolism after bone marrow aspiration and biopsy

Önal I., Sümer H., TUFAN A., Shorbagi A.

AMERICAN JOURNAL OF HEMATOLOGY , vol.78, no.2, pp.158, 2005 (SCI-Expanded, Scopus)

76. Frequency of HFE mutations among Turkish blood donors according to transferrin saturation

Simsek H., Sumer H., Yilmaz E., BALABAN H. Y., Ozcebe O., Hascelik G., et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY , vol.38, no.8, pp.671-675, 2004 (SCI-Expanded, Scopus)

77. Herediter Hemochromatozis

SÜMER H., ŞİMŞEK H., TATAR G.

Türkiye Klinikleri Journal Of Microbiology-Infection (kronik hepatit özel sayısı) , vol.2, no.3, pp.184-194, 2003 (Peer-Reviewed Journal)

Papers Presented at Peer-Reviewed Scientific Conferences 117

1. Histological and clinical disease progression in patients with metabolic associated steatotic liver disease using paired biopsy

ekelik m., TURAN D., GÜMÜŞSOY M., KİREMİTCİ S., BODAKÇİ E., yılmaz V., et al.

EASL congress 2024, 05 June 2024, (Summary Text)

2. Requrrence of primary sclerosing cholangitis after living donor liver transplantation: experience from turkish registery

ADALI G., harputluoğlu m., AKDOĞAN KAYHAN M., TURAN D., AKARSU M., DANIŞ N., et al.

EASL congress 2024, 05 June 2024, (Summary Text)

3. The impact of tumor budding in patients with hepatocelular carcinoma

Duran o. f., GÖKCAN H., KİREMİTCİ S., YILMAZ V., ÇİFTÇİ A., BODAKÇİ E., et al.

EASL congress 2024, 05 June 2024, (Summary Text)

4. DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE USING PAIRED LIVER BIOPSY

TURAN GÖKÇE D., Ekelik M. M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.

Digestive Disease Week (DDW), Washington, Kiribati, 18 - 21 May 2024, vol.166, (Summary Text)

5. Assessing Hepatic Steatosis by Magnetic Resonance Imaging in Potential Living Liver Donors

Kuru Öz D., Ellik Z., Gürsoy Çoruh A., Gümüşsoy M., Adıgüzel M., Kiremitci S., et al.

AASLD-TASL Hepatology Connect Meeting 2024, İzmir, Turkey, 16 - 17 February 2024, pp.1-2, (Summary Text)

6. Hepatic steatosis is associated with HbsAg clearnce in patients with chronic hepatitis B infection

BODAKÇİ E., DUMAN S., KİREMİTCİ S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., ER R. E., et al.

AASLD-TASL hepatology connect meeting 2024, 16 February 2024, (Summary Text)

7. SAT-519 The impact of tumor budding on tumor biology in patients with hepatocellular carcinoma

DURAN O. F., GÖKCAN H., KİREMİTCİ S., GÜVENİR S. T., YILMAZ V., BODAKÇİ E., et al.

AASLD-TASL hepatology connect meeting, 16 February 2024, (Full Text)

8. C282Y mutation in hemochromatosis: Single center experience

BODAKÇİ E., GÖKCAN H., GÜMÜŞSOY M., GÜVENİR S. T., YILMAZ V., KARAKAYA M. F., et al.

AASLD-TASL hepatology connect meeting 2024, 16 February 2024, (Summary Text)

9. Assesing Hepatic Steatosis by MRI in potential living liver donors

Kuru Öz d., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., kırımker o. e., GÖKCAN H., et al.

AASLD-TASL hepatology connect meeting 2024, 16 February 2024, (Summary Text)

10. Histological and Clinical disease Progression in Patients with Metabolic Dysfuntion associated Steatotic Liver Disease Isinig Paired Biopsy

Ekelik M. M., TURAN D., GÜMÜŞSOY M., KİREMİTCİ S., BODAKÇİ E., YILMAZ V., et al.

AASLD-TASL hepatology connect meeting 2024, 16 February 2024, (Summary Text)

11. The impact of tumor budding on tumor biology in patients with hepatocellular carcinoma

Duran O. F., GÖKCAN H., KİREMİTCİ S., GÜVENİR S. T., YILMAZ V., BODAKÇİ E., et al.

AASLD-TASL hepatology connect meeting 2024, 16 February 2024, (Summary Text)

12. Familial NAFLD Cirrhosis Case Series

AKARCA H. T., GÖKCAN H., GÜVENİR S. T., YILMAZ V., İDİLMAN R.

19. Euroasian Hepatogastroenterology and Surgery, 13 November 2023, (Full Text)

13. Case series of C282Y mutation in the HFE gene in Turkey: Single-center experience

BODAKÇİ E., GÖKCAN H., güvener t., YILMAZ V., ER R. E., KARAKAYA M. F., et al.

19. Euroasian Hepatogastroenterology and Surgery, 13 November 2023, (Full Text)

14. Gastric bronchogenic cyst mimicking pancreatic mucinous cyst

duran o. f., GÖKCAN H., KACAR S., AKDOĞAN KAYHAN M., BOSTANCI E. B.

19. Euroasian Hepatogastroenterology and Surgery, 13 November 2023, (Full Text)

15. noninvazive fibrosis markers for assesment for liver fibrosis in patients with chronic hepatitis delta

KARAKAYA M. F., KURU ÖZ D., Turan Gökçe D., DUMAN S., Ellik Z. M., GÜMÜŞSOY M., et al.

AASLD 2023 congress, 10 November 2023, (Full Text)

16. Noninvazive fibrosis markers for assesment for liver fibrosis in patients with chronic hepatitis delta

KARAKAYA M. F., KURU ÖZ D., Turan D., DUMAN S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., et al.

AASLD 2023 congress, United States Of America, 10 November 2023, (Summary Text)

17. NON - INVASIVE FIBROSIS MARKERS FOR ASSESMENT OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS DELTA

BODAKÇİ E., KARAKAYA M. F., KURU ÖZ D., Gokce D., DUMAN S., Ellik Z., et al.

Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, vol.78, (Summary Text)

18. development of Metabolic Disorders in Transplant Recepients

Erdemir G., GÖKCAN H., Gürsoy Çoruh A., GÜLPINAR B., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., et al.

EASL Congress 21-24 June 2023, Austria, 21 - 24 June 2023, vol.78, pp.477-478, (Full Text)

19. development of Metabolik disorders in Liver transplant recepients

Erdemir G., GÖKCAN H., İDİLMAN R.

The 2023 International congress of ILTS ELITA and LICAGE, 03 May 2023, (Full Text)

20. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.

DUMAN S., KURU ÖZ D., GÜMÜŞSOY M., KİREMİTCİ S., GÖKCAN H., ÖZERCAN A. M., et al.

AASLD-TASL hepatology connect meeting, 28 - 29 April 2023, (Full Text)

21. Natural Disease outcome in patients with NAFLDÇ a study with paired liver biopsies

GÜMÜŞSOY M., TURAN D., ekelik m., KİREMİTCİ S., DUMAN S., GÜVENİR S. T., et al.

AASLD-TASL hepatology connect meeting, 28 April 2023, (Full Text)

22. A case of AFP producing cholangiocarcinoma

BODAKÇİ E., GÜMÜŞSOY M., GÜVENİR S. T., KARAKAYA F., GÖKCAN H., İDİLMAN R.

AASLD-TASL hepatology connect meeting, 28 - 29 April 2023, (Full Text)

23. effect of prognostic tests on disease outcome of alcohol-related liver disease

zengin b. a., GÜMÜŞSOY M., DUMAN S., BODAKÇİ E., ÖZERCAN A. M., ER R. E., et al.

AASLD-TASL hepatology connect meeting, 28 April 2023, (Full Text)

24. Development of Metabolic Disorders in Transplant Recepients

erdemir g., GÖKCAN H., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.

AASLD-TASL hepatology connect meeting, 28 - 29 April 2023, (Full Text)

25. İdentification of risk factors for alcohol relapse in liver transplant patients with alcohol- related liver disease.

TURAN D., GÜNŞAR F., harputluoğlu m., KABAÇAM G., GÖKCAN H., AKARSU M., et al.

EASL Congress 21-24 June 2023, 21 April 2023, (Full Text)

26. A Combination Of Non-Invasive Tests In Detection Of NAFLD-Related Advanced Fibrosis Is Not Superior To MRE Alone

Duman S., Gümüşsoy M., Kuru D., Kiremitci S., Gökcan H., Bodakçı E., et al.

39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber, Bochum, Germany, 27 - 28 January 2023, vol.61, pp.30, (Summary Text)

27. Alkole Bağlı Karaciğer Hastalığında Prognostik Non-İnvasif Testlerin Hastalık Sonucunu Öngörmede Etkinliği

ZENGİN B. A., GÜMÜŞSOY M., DUMAN S., BODAKÇİ E., GÜVENİR S. T., MELEKOĞLU ELLİK Z., et al.

39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 22 November 2022, (Summary Text)

28. Alkol Dışı Yağlı Karaciğer Hastalığı Doğal Seyri: Ardışık İkili Karaciğer Biyopsilerinin Karşılaştırılması

GÜMÜŞSOY M., TURAN D., EKELİK M., KİREMİTCİ S., BODAKÇİ E., DUMAN S., et al.

39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 22 November 2022, (Summary Text)

29. Natural disease Outcome in patients with NAFLD: A study with paired liver biopsy

GÜMÜŞSOY M., Turan Gökçe D., KİREMİTCİ S., BODAKÇİ E., DUMAN S., MELEKOĞLU ELLİK Z., et al.

aasld 2022, 04 November 2022, (Summary Text)

30. Metabolic Syndrome in liver Transplant recipient

KARA G., GÖKCAN H., İDİLMAN R.

AASLD 2022, 4 - 08 November 2022, (Summary Text)

31. Trends and causes of etiology in adult liver transplant patients: multicenter study

AKARSU M., Harputluoğlu M., YILMAZ S., GENÇDAL G., AKYILDIZ M., DİNÇER D., et al.

ınternational Liver congress ILC 2022 (EASL), 22 - 26 June 2022, (Summary Text)

32. Preliminary Results of The effectiveness and safety of Tenofovir alafenamide Fumarate Prophylaxis in HBV individuals, who received Chemo/Immunsupression therapy

GÜNDÜZ F. F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM A. E., et al.

ınternational Liver congress ILC 2022 (EASL), 22 June 2022, (Summary Text)

33. The effect of clinicopathologic findings of hepatocellüler carcinoma on post transplant survival: a multicenter cohort from TASL Liver transplantation special group

AKYILDIZ M., GENÇDAL G., İNCE V., ZEYTÜNLÜ M., TURAN İ., GÜNŞAR F., et al.

ınternational Liver congress ILC 2022 (EASL), 22 - 26 June 2022, (Summary Text)

34. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patients with hepatitis B virus related cirrhosis

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., ADANIR H., GÜNDÜZ F. F., et al.

ınternational Liver congress ILC 2022 (EASL), 22 - 26 June 2022, (Summary Text)

35. Effectiveness of MRI methods in the asssement of hepatic steatosis in living liver donors

KURU ÖZ D., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMANLI S., ER R. E., et al.

ınternational Liver congress ILC 2022 (EASL), 22 June 2022, (Summary Text)

36. Real life efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: a multicenter study (SAT416)

GÖKCAN H., YAPALI S., HARPUTLUOĞLU M. M. M., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., et al.

EASL The International Liver Congress, London, Canada, 26 June 2022, (Summary Text)

37. Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421)

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., GÜZELBULUT F., VATANSEVER S., et al.

EASL The International Liver Congress, London, Canada, 22 June 2022, (Summary Text)

38. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: A multicenter study

YAPALI S., GÖKCAN H., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., DURAK S., et al.

ILTS 2022, 04 May 2022, (Summary Text)

39. Real life efficacy and tolerability of tenofovir alafenamde fumarate in liver transplant recipients: A multicenter study

YAPALI S., GÖKCAN H., harputluoğlu M., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., et al.

AASLD TASL Digital Hepatology Meeting, Turkey, 14 - 15 January 2022, vol.3, pp.4, (Full Text)

40. Biliary complications and management in liver transplant recipients with duct to duct anastomosis: A single center experience

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.

AASLD-TASL Digital Hepatology Meeting, 14 January 2022, (Summary Text)

41. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patiernts with hepatitis B virus related cirrhosis

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., VATANSEVER S., ADANIR H., et al.

AASLD-TASL digital Hepatology Connect, 14 April 2022, (Summary Text)

42. Development of Metabolic Disorders İn Liver Transplant Patients

KARA G., GÖKCAN H., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.

AASLD-TASL digital Hepatology Connect, 14 January 2022, (Summary Text)

43. Bliary Complications and Management in Liver Transplant Patients with Duct to Duct Anastomotis: Single Center Experience

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.

AASLD-TASL digital Hepatology Connect, 14 January 2022, (Summary Text)

44. Presentation and outcome of autoimmune hepatitis during pregnancy

örmeci a., DUMAN S., İSTEMİHAN Z., GÖKCAN H., ÇAVUŞ B., ARSLAN K., et al.

AASLD-TASL digital Hepatology Connect, 14 January 2022, (Summary Text)

45. The Effect of Clinicopathologic findings of Hepatosellüler carcinoma on posttransplant survival: A multicenter kohort from TASL Liver Transplantation special İnterest group

AKYILDIZ M., GENÇDAL G., İNCE V., Harputluoğlu M., ZEYTÜNLÜ M., KILIÇ M., et al.

AASLD-TASL digital Hepatology Connect, 14 - 16 January 2022, (Full Text)

46. Efficacy and Safety of Tenofovir alafenamide in hepatitis B virus infected patients with chronic hemodialsis and renal transplantation: a preliminary result

ADANIR H., ÖZER ETİK D., YILDIRIM A. E., YAPALI S., ARI D., GÖKCAN H., et al.

AASLD-TASL digital Hepatology Connect, 14 January 2022, (Summary Text)

47. Trends and changes of etiology in adult liver transplant patients: mulitcenter study

AKARSU M., Harputluoğlu M., YILMAZ S., AKYILDIZ M., GENÇDAL G., polat k. y., et al.

AASLD-TASL digital Hepatology Connect, 14 January 2022, (Full Text)

48. Kemoterapi ve İmmünosüpresif Tedavi Alan Hastalarda Hepatit B Reaktivasyon Profilaksisinde Tenofovir Alafenamid Fumaratın Etkinliği ve Güvenliği: Çok Merkezli-Gözlemsel Çalışmanın ilk Sonuçları

GÜNDÜZ F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM E., et al.

38. Ulusal Gastroenteroloji Haftası 16-21 Kasım 2021, Antalya, 16 November 2021, (Summary Text)

49. Tenofovir Alafenamid Fumaratın Hepatit B virüsü ile İlişkili Sirozlu Hastalar ve Post-transplant Hastalarda Gerçek Yaşam Etkinliği ve Tolere Edilebilirliğinin Ön Sonuçları

YAPALI S., GÖKCAN H., HARPUTLUOĞLU M., MELEKOĞLU ELLİK Z., AKARSU M., DURAK S., et al.

38. Ulusal Gastroenteroloji Haftası 16-21 Kasım 2021, Antalya, 16 November 2021, (Summary Text)

50. ’Duct to Duct Anastomozlu’ Karaciğer Transplantasyon Hastalarında Biliyer Komplikasyonlar ve Yönetimi: Tek Merkez Deneyimi

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.

38. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 16 November 2021, (Summary Text)

51. Real life Efficay and Tolerability of Tenofovir alafanamide fumarate in patients with hepatitis B virus related cirrhosis and liver transplant recepients: a prilimanary result

YAPALI S., GÖKCAN H., Harputluoğlu M., MELEKOĞLU ELLİK Z., AKARSU M., ADANIR H., et al.

AASLD 2021 congress, 05 November 2021, (Summary Text)

52. Karaciğer Donörlerinin Preoperatif Yağlanma Değerlendirilmesinde MRG Yöntemlerinin Etkinliği

Kuru Öz D., Melekoğlu Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Duman S., et al.

38. Ulusal Gastroenteroloji Haftası, 2021, Antalya, Turkey, 16 October - 21 November 2021, pp.160-161, (Summary Text)

53. Real Life Efficacy and Tolerability of Tenofovir Alafenamide Fumarate in Patients with Hepatitis B Virus-related Cirrhosis and Liver Transplant Recipients. A-Preliminary Result (798)

YAPALI S., GÖKCAN H., HARPUTLUOĞLU M. M. M., MELEKOĞLU ELLİK Z., AKARSU M., DURAK S., et al.

AASLD the Liver Meeting Digital Experience, United States Of America, 12 November 2021, vol.74, pp.490, (Summary Text)

54. Efficacy and Safety of TAF in Hepatitis B virus infected patiebts with chronic hemodialiss and renal transplantation: A prelimanry result

ADANIR H., etik d. ö., YILDIRIM A. E., YAPALI S., COŞAR A. M., ARI D., et al.

AASLD 2021 congress, 06 November 2021, (Summary Text)

55. association. between non-alcoholic fatty liver disease and extrahepatic malignancy

GÜMÜŞSOY M., İDİLMAN R., GÖKCAN H., BODAKÇİ E., özercan m., ER R. E., et al.

EASL gongress 2021, 23 June 2021, (Summary Text)

56. Kemoterapi ve İmmünsüpresif Tedavi Alan Hastalarda Hepatit B Reaktivasyon Profilaksisinde Tenofovir Alafenamide Fumarat’ın Etkinliği ve Güvenirliği: Çok Merkezli-Gözlemsel Çalışmanın İlk Sonuçları

GÜNDÜZ F., ÜNSAL Y., MELEKOĞLU ELLİK Z., MEHDİYEV S., YILDIRIM E., ADANIR H., et al.

13. ULUSAL HEPATOLOJİ KONGRESİ ULUSLARARASI KATILIMLI, 28 - 30 May 2021, (Summary Text)

57. EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS WITH CHRONIC HEMODIALYSIS AND KIDNEY TRANSPLANTATION‐ REALITY STUDY

ADANIR H., MELEKOĞLU ELLİK Z., YILDIRIM A. E., GÜNDÜZ F. F., GÖKCAN H., YARAŞ S., et al.

AASLD‐TASL Digital Hepatology Connect Meeting, 2021, 15 September 2021, (Summary Text)

58. Non-alcoholic fatty liver disease and extrahepatic malignancy

Gümüşsoy M., Turan Gökçe D., Ulaş B. B., Koç Ö., Karataş G., Bodakçı E., et al.

AASLD-TASL digital Hepatology Connect, 15 January 2021, (Full Text)

59. The analysis of liver transplant patients with COVİD-19 infection: a national cohort

KABAÇAM G., TURAN İ., KIYICI M., MELEKOĞLU ELLİK Z., dolu S., Dayangaç M., et al.

AASLD-TASL digital Hepatology Connect, İstanbul, Turkey, 15 - 16 January 2021, vol.2, pp.24-25, (Summary Text)

60. Direkt Etkili Antiviral Ajanlarla Tedavi Olan Hepatit C Hastalarında Noninvaziv Fibrozis İndeks Değerlerinin Değişimi

ARI D., TURAN GÖKÇE D., GÖKCAN H., BACAKSIZ F., ÖZTÜRK Ö., KACAR S., et al.

37. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2020, (Summary Text)

61. Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: a multicenter study

TURAN İ., ALADAĞ M., Harputluoğlu M., YILMAZ S., GENÇDAL G., ÖZÇAY F., et al.

The digital İnternational Liver Cogress, 27 August 2020, (Summary Text)

62. Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.

DEMİR M., DANIŞ N., KANİ H. T., YILDIRIM A. E., BALKAN A., DEĞERTEKİN M. B., et al.

APASL Single Topic Conference, İstanbul, Turkey, 27 - 29 September 2018, (Summary Text) Sustainable Development

63. Endoskopik İşlemler İçin Başvuran Hastalarda Hepatit B ve C Enfeksiyonlarının Farkındalık Düzeyi

GÖKCAN H., OZTAŞ E., ÖNAL İ. K.

32. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 25 - 29 November 2015

64. Splenosis Vaka Bildirimi

KAÇAR S., ÖZDEMİR M., YILDIRIM Ş., KERİMEL İ., GÖKCAN H., UFUK BARIŞ K., et al.

” 12. Ulusal Hepato Gastroenteroloji Kongresi 3. Ulusal Gastroenteroloji&Cerrahisi Kongresi, AFYON, Turkey, 8 - 10 October 2015, vol.128

65. Groove Pankreatit İki Vaka sunumu

KAÇAR S., ZENGİN N. İ., AYDOĞ G., ÖZER İ., ÖZDEMİR M., ÖLÇÜCÜOĞLU E., et al.

12. Ulusal Hepato Gastroenteroloji Kongresi &3. Ulusal Gastroenteroloji Cerrahisi Kongresi, AFYON, Turkey, 8 - 10 October 2015, pp.129

66. Fokal noduler hiperplazi içeren canlı vericiden başarılı bir karaciğer nakli olgusu

GÖKCAN H., AKDOĞAN KAYHAN M., KAÇAR S., ÖKTEN R. S., ÖZDEMİR M., TURHAN N., et al.

10. Ulusal hepatoloji Kongresi, İstanbul, Turkey, 27 - 30 May 2015

67. Karaciğer Nodüllerinin Ayırıcı Tanısında Bilgisayarlı Tomografinin Tanısal Değeri

GÖKCAN H., AKDOĞAN KAYHAN M., KAÇAR S., ÖKTEN R. S., TURHAN N., ÖZDEMİR M., et al.

10. Ulusal hepatoloji Kongresi, İstanbul, Turkey, 27 - 30 May 2015, pp.198